Changes in Ovarian Cancer Prognosis, Ten Years Single Center Experience

INTRODUCTION: Ovarian cancer is the fifth most common cancer in women and ranks first among the causes of death due to gynecological cancers. In our study, we aimed to evaluate the recurrence status, survival outcomes and treatment-related side effects of patients treated for ovarian cancer retrospectively.
METHODS: The study is performed at Dr.Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. In this study, 160 patients with ovarian cancer who were followed up for diagnosis and treatment between January 2010 and January 2020 were analyzed retrospectively. The cases were analyzed according to the average age, histopathological types of the ovarian cancer, the stage at the time of diagnosis, the side effects associated with the chemotherapy, the progression-free survival (PFS) and overall survival (OS) rates.Log-Rank test was used to determine survival times.
RESULTS: The median age of patients included in the study is 61 ± 11 (50-72). Serous epithelial ovarian cancer was the most common (80.6%) according to histopathological subgroups. When the stage distribution at the time of diagnosis was examined, it was seen that the cases were mostly diagnosed in Stage III. While the most common side effect associated with chemotherapy was alopecia (100%), the incidence of side effects other than alopecia was 51.2%. Recurrence was detected in 48.8% of the cases, and median progression-free survival was 19.1 months, and overall survival was 89.9 months in the whole group.. Overall survival was significantly low in cases with dose reduction (p <0.05).
DISCUSSION AND CONCLUSION: The present study shows similarity with other studies in terms of mean age, stage of diagnosis, chemotherapy side effects, survival rates. The negative effect of dose reduction on overall survival is similar to most studies, but the necessity of new research on this subject is noticeable.

Over Kanseri Prognozunda Deðiþiklikler, On Yýllýk Tek Merkez Deneyimi

GÝRÝÞ ve AMAÇ: Over kanseri kadýnlarda görülen beþinci en sýk kanser olmakla birlikte jinekolojik kanserlere baðlý ölüm nedenleri arasýnda ilk sýrada yer almaktadýr. Çalýþmamýzda merkezimizde over kanseri nedeniyle tedavi verilen hastalarýn nüks durumunun, saðkalým sonuçlarýnýn ve tedaviye baðlý gözlenen yan etkilerin retrospektif olarak deðerlendirilmesi amaçlanmýþtýr.
YÖNTEM ve GEREÇLER: Çalýþmamýzda Ocak 2010 –Ocak 2020 yýllarý arasýnda Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eðitim ve Araþtýrma Hastanesi Medikal Onkoloji Kliniðinde taný ve tedavi amacýyla takibi yapýlmýþ over kanserli 160 olgunun týbbi kayýtlarý sistem notlarý ve dosyalarýndan retrospektif olarak incelenmiþtir. Çalýþmamýza over kanseri tanýsý almýþ 18 yaþ ve üzeri hastalar dahil edildi. Olgular yaþ ortalamasýna, over kanseri histopatolojik tiplerine, taný anýndaki evreye, aldýklarý kemoterapiye baðlý görülen yan etkilerine, progresyonsuz saðkalým (PFS) ve genel saðkalým (GS) sürelerine göre ayrýntýlý olarak incelenmiþtir. Saðkalým sürelerinin hesaplanmasýnda Kaplan–Meier analizi kullanýldý.
BULGULAR: Çalýþmaya alýnan 160 hastanýn ortanca yaþý 61 ± 11 idi. Histopatolojik alt gruplara göre en sýk (%80,6) seröz epitelyal over kanseri saptandý. Taný esnasýndaki evre daðýlýmý incelendiðinde olgularýn en çok Evre III’de taný aldýðý görüldü. Kemoterapiye baðlý en sýk görülen yan etki alopesi (%100) olurken; alopesi dýþýnda yan etki görülme insidansý %51,2 olarak bulundu. Olgularýn %48,8’inde nüks saptanýrken; medyan progresyonsuz saðkalým 19,1 ay; tüm grupta ise genel saðkalým 89,9 ay olarak hesaplandý. Doz azaltýmý yapýlan olgularda ise genel saðkalým anlamlý olarak düþük bulundu (p<0,05).
TARTIÞMA ve SONUÇ: Çalýþmamýz olgularýn yaþ ortalamasý, hastalýðýn tanýdaki evresi, kemoterapi yan etkileri, saðkalým oranlarý açýsýndan diðer çalýþmalarla benzerlik göstermektedir. Doz azaltýmýnýn genel saðkalým üzerine olan negatif etkisi ise çoðu çalýþma ile benzerlik göstermekle birlikte bu konuda yapýlacak yeni araþtýrmalarýn gerekliliði göze çarpmaktadýr.